Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Fig. 2

Incremental cost per responder over 24 weeks among the overall population. a Incremental cost per additional ACR50 responder vs. incremental cost per additional PASI75 responder. b Incremental cost per additional ACR70 responder vs. incremental cost per additional PASI90 responder. ADA, adalimumab; APR, apremilast; CZP, certolizumab pegol; ETN, etanercept; GOL, golimumab; IFX, infliximab; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; UST 45, ustekinumab 45 mg; UST 90, ustekinumab 90 mg

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us